Address: 13F, No.3 Park St NanKang Dist. Taipei, Taiwan 115 ,Taiwan
Tel: +886-2-2655-7688
Web: http://www.pharmaessentia.com/
PharmaEssentia Corporation is a global pharmaceutical company founded by a group of eminent Taiwanese-American scientists in August 2003. Its mission is to discover, develop, and deliver to the market a range of efficacious, safe and cost-effective therapeutic products for human disease through new drug research and development. Its mission is a never-ceasing quest for the improvement of the health and quality of human life.
PharmaEssentia strives to utilize the most modern biotechnology science to fulfill its mission, under the following strategy:
1. Build and position intellectual property for all desired target areas, and to generate short term revenue to boost the
company’s market value.
2. Leverage strategic collaborations to minimize capital investment and to facilitate the delivery of product to the market. 3. Strengthen platform technology to become a worldleading biotechnology company.
Ko-Chung Lin, founder and CEO of PharmaEssentia, documents the main specificities of the company’s groundbreaking ropeginterferon alfa-2b, a once-every-two-week interferon displaying a unique toxicity profile. In this regard, Mr. Lin…
When you created PharmaEssentia, what was the rationale behind coming back to Taiwan? The foundation for the company was laid in 1997. A group of Taiwanese government officials came to…
As a part of the World Health Organisation’s (WHO) COVID-19 Technology Access Pool (C-TAP), the Medicines Patent Pool has signed a worldwide license with Medigen Vaccine Biologics (MVC) for its…
In an important milestone for Taiwan’s biotech industry, Diamond Biofund – one of the territory’s most well-established venture capital (VC) funds – became the first such firm to list on…
The latest pharma news from Taiwan, including Gongwin-KY’s lung cancer drug approval in China, Anxo Pharmaceutical/Genovior Biotech alliance, Taiwan’s Industrial Technology Research Institute (ITRI) and Metagone Biotech’s glaucoma and macular…
The latest healthcare and pharma news from Taiwan, including the CDMO Bora Pharmaceutical’s acquisition of Eden Biologics assets, the FDA fast track granted to the Taiwanese biomedical group United Biomedical’s…
Charles Chen of Taiwanese firm Medigen Vaccines Biologics Corp (MVC) shares his career journey, the company’s COVID-19 vaccine strategy, and what MVC’s competitive advantages are. At MVC we have…
Johnsee Lee and Eric Yang of Taiwanese precision medicine diagnostics firm Quark Biosciences outline their technology’s unique characteristics, how it differs from sequencing technologies in terms of cost and speed,…
Louis Cheng, CEO of Taiwanese firm Leadgene Biomedical, introduces the company’s expertise in antibody technologies, his ambitious internationalization plans, and comments on the vital role that companies like Leadgene have…
Taiwan Bio Industry Organization Chairman Dr Johnsee Lee outlines the Taiwanese biopharmaceutical industry’s rapid and coordinated response to the COVID-19 crisis and also explains how Quark Biosciences’ diagnostics and precision…
Taiwan, although small in size, boasts a strong culture of innovation as well as a universal healthcare system that is the envy of its neighbours. Here, three country managers for…
Long overshadowed by larger and more well-known neighbours, the island of Taiwan is nonetheless cultivating an enviable reputation at the forefront of some of the most innovative trends shaping global…
While Taiwanese pharmaceutical and biotech players have traditionally set their sights on the US as a key market, rising medical needs in Asia are helping foster more regionally-focused strategies. …
All country managers of multinational pharma companies need to strike the balance between having a global outlook and adapting to local culture. For BoonHuey Ee, general manager of Merck Biopharma…
See our Cookie Privacy Policy Here
